FDA human factors expectations take effect: submissions received from 1 August 2026 should follow the new risk-based framework

Written By Rado Milkov

Standfirst: The FDA's 60-day operationalisation window for its final human factors guidance closed on 1 August 2026. From that date the Agency expects marketing submissions to CDRH to apply the guidance's risk-based Human Factors Submission Categories. The guidance is non-binding, but review efficiency now depends on it.


Date of development: 1 August 2026 (end of FDA's stated operationalisation period) Date of publication: 3 August 2026

Key takeaways

  • The FDA's final guidance Content of Human Factors Information in Medical Device Marketing Submissions was issued in May 2026 and announced in the Federal Register on 29 May 2026 (91 FR 32061, Docket FDA-2015-D-4599).

  • The Agency stated it anticipated needing a minimum of 60 days to operationalise the policy. That window closed on 1 August 2026 — a date that fell within the past week.

  • For submissions received before 1 August 2026, the FDA said it generally did not anticipate manufacturers would be ready to include the newly recommended information. That accommodation has now lapsed for new submissions.

  • The guidance applies to 510(k) premarket notifications, De Novo requests, PMAs and HDE applications reviewed by CDRH.

  • It is a non-binding guidance issued under 21 CFR 10.115. Alternative approaches remain available if they satisfy applicable statutes and regulations.

What happened

On 29 May 2026 the FDA announced in the Federal Register (91 FR 32061) the availability of a final guidance titled Content of Human Factors Information in Medical Device Marketing Submissions. The guidance provides a risk-based framework for the human factors information that should be included in a marketing submission to the Center for Devices and Radiological Health (CDRH), with the stated aim of improving the efficiency of FDA review.


In the same notice, and repeated on the FDA's guidance landing page, the Agency set out its transition expectation in these terms: it "recognizes and anticipates that the Agency and industry may need a minimum of 60 days to perform activities to operationalize the policies within this guidance", and that for submissions pending after publication "as well as those submissions received before August 1, 2026, FDA generally does not anticipate that manufacturers will be ready to include the newly recommended information outlined in the guidance in their submission." The FDA added that it intends to review such information if submitted at any time.


That threshold — 1 August 2026 — passed during the week under review. It is the reason this item appears in this edition. The underlying guidance is not new; the point at which the FDA's stated accommodation stops applying is.

What is new compared with the previous position

Item Before 1 August 2026 From 1 August 2026
FDA expectation for new marketing submissions Agency generally did not anticipate manufacturers would include the newly recommended human factors information Accommodation no longer stated for submissions received on or after this date
Governing guidance 2022 draft guidance; 2016 draft List of Highest Priority Devices for Human Factors Review Final May 2026 guidance, complementing Applying Human Factors and Usability Engineering to Medical Devices
Framework Priority-list approach in the 2016 draft, superseded by the 2022 draft’s risk-based approach Risk-based Human Factors Submission Category framework, with additional risk factors, new illustrative examples and appendices, and clarified scope relative to the 2022 draft

The Federal Register notice records that, following comments on the 2022 draft, the FDA revised the guidance to include "additional risk-based factors to consider when determining the Human Factors Submission Category, new illustrative examples and Appendices, and clarifications to the scope of the guidance."

Why this matters in practice

FDA guidance is not binding, and the notice is explicit that the document "does not establish any rights for any person and is not binding on FDA or the public." In practice, however, a CDRH guidance that describes what reviewers expect to see functions as the reference point for completeness review and for deficiency letters. Where a submission does not follow the framework, the burden shifts to the sponsor to explain why its alternative satisfies the underlying requirements.


The commercial consequence is time. Human factors deficiencies are a recognised source of additional information requests in 510(k) and De Novo review, and each cycle adds calendar weeks to a launch plan. Applying the categorisation framework correctly at the point of submission is a cheaper exercise than defending an unstructured approach mid-review.


For European manufacturers pursuing parallel EU and US routes, there is also a documentation-reuse question. Usability engineering work performed under IEC 62366-1 for MDR purposes will frequently supply much of the underlying evidence, but the FDA framework governs how that evidence is categorised and presented in a CDRH submission. The two are not interchangeable without deliberate mapping.

Who is affected

  • Manufacturers preparing 510(k), De Novo, PMA or HDE submissions to CDRH

  • Combination product sponsors where the device constituent is reviewed by CDRH

  • Regulatory affairs teams managing parallel EU and US submissions

  • Human factors and usability engineering functions, and the consultancies supporting them

  • EU-based manufacturers entering or expanding in the US market

Key dates

Date Event
3 February 2016 FDA announces draft guidance List of Highest Priority Devices for Human Factors Review (81 FR 5756)
9 December 2022 Revised draft guidance issued (87 FR 75635), replacing the 2016 draft
28 May 2026 Final guidance issued; document placed on public inspection
29 May 2026 Federal Register notice of availability published (91 FR 32061)
1 August 2026 End of the FDA’s stated 60-day operationalisation accommodation


Practical actions to consider

  1. Determine the Human Factors Submission Category for each device currently in preparation, and record the reasoning. Where a submission was in late-stage preparation before 1 August 2026, decide deliberately whether to re-categorise or to explain the approach in a cover letter.

  2. Map existing IEC 62366-1 usability engineering files to the FDA framework rather than resubmitting them unstructured. The evidence is often already there; the presentation is what changes.

  3. Check whether your submission templates prompt for the new content. Secondary commentary suggests the eSTAR templates were updated to reflect the guidance; this should be confirmed directly against the current templates rather than assumed.

  4. Use the Q-Submission programme where categorisation is genuinely ambiguous — particularly for devices with novel user interfaces, home-use devices or significant user-interface modifications.

  5. Revisit the companion guidance. The final guidance is expressly a companion to Applying Human Factors and Usability Engineering to Medical Devices, and the FDA indicated at draft stage that it intended to revise that document on finalisation. Track whether and when that revision appears.

Open questions

  • Whether the FDA will apply the framework strictly to submissions received shortly after 1 August 2026, or continue exercising review discretion in practice. The notice does not say.

  • Whether and when Applying Human Factors and Usability Engineering to Medical Devices will be revised.

  • The precise content of the final guidance's appendices and examples. See the review note below — the substantive text could not be retrieved from the FDA's own download endpoint at the time of writing.

QLE perspective

We would treat 1 August 2026 as an administrative rather than a legal cliff edge. Nothing became unlawful; a stated accommodation simply lapsed. The realistic risk is not rejection but review friction — an additional information request, and the schedule slip that follows.


For QLE's EU-based clients, the more useful framing is portfolio-level: if you maintain usability engineering files to IEC 62366-1 for MDR purposes, the incremental work to satisfy the FDA framework is presentational rather than evidential in most cases. The organisations that struggle tend to be those treating human factors as a late-stage documentation exercise rather than a design-phase activity, and that is a quality-system question before it is a submission question.


We are not in a position to offer a view on the detailed content of the final guidance, because we were unable to retrieve the final text from the FDA's published download link. That limitation is recorded in the verification section, and we would not want it read as a judgement on the guidance itself.

Conclusion

Has anything changed legally for US device submissions? No. The guidance remains non-binding and the statutory requirements are untouched. What changed on 1 August 2026 is the FDA's stated expectation of readiness. Sponsors filing from this point should assume reviewers will look for the risk-based Human Factors Submission Category framework, and should be prepared to justify any departure from it.

Sources


Rado Milkov
Next

AI Act's Digital Omnibus is now law: AI medical devices get until 2 August 2028, but notified bodies face a 28 January 2028 deadline